Edition:
India

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

615.00GBp
18 May 2018
Change (% chg)

-14.50 (-2.30%)
Prev Close
629.50
Open
612.00
Day's High
626.50
Day's Low
605.00
Volume
1,959,600
Avg. Vol
760,594
52-wk High
784.00
52-wk Low
540.00

Latest Key Developments (Source: Significant Developments)

BTG full-year operating profit up 18 pct
Tuesday, 15 May 2018 

May 15 (Reuters) - BTG PLC ::FY REVENUE 620.5 MILLION STG, UP 9 PERCENT.ADJUSTED OPERATING PROFIT 152.7 MILLION STG, UP 18 PERCENT.ADJUSTED BASIC EPS 1 32.9P UP 42 PERCENT.  Full Article

BTG says 2017/18 results hit by 150 million pound impairment charge
Thursday, 5 Apr 2018 

April 5 (Reuters) - BTG PLC ::BTG HAS DELIVERED A GOOD FINANCIAL PERFORMANCE FOR YEAR, WITH REVENUE IN LINE WITH EXPECTATIONS.VERY GOOD GROWTH IN INTERVENTIONAL MEDICINE PRODUCT SALES REFLECTS MID-TEENS CER 1 GROWTH IN ONCOLOGY AND VASCULAR PORTFOLIOS, WHICH TOGETHER REPRESENT >90% OF REVENUE IN THIS BUSINES.LOWER SALES OF PNEUMRX ® COILS REFLECT THAT MARKET DEVELOPMENT, INCLUDING SECURING APPROPRIATE LEVELS OF REIMBURSEMENT, IS TAKING LONGER THAN EXPECTED.WE DO NOT EXPECT MATERIAL REVENUES FROM THIS PRODUCT OVER NEXT TWO YEARS.WE HAVE THEREFORE REASSESSED FAIR VALUE OF THIS ASSET, AND OUR FINANCIAL RESULTS FOR 2017/18 WILL INCLUDE AN IMPAIRMENT CHARGE OF APPROXIMATELY £150M.IN ADDITION, OUR 2018/19 RESULTS WILL INCLUDE A ONE-OFF RESTRUCTURING CHARGE OF UP TO £10M.  Full Article

BTG says Zytiga royalties guidance unchanged after patent setback
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - BTG ::SPOKESMAN SAYS PREVIOUS GUIDANCE ON ZYTIGA ROYALTIES IS UNCHANGED, DESPITE U.S. ADMINISTRATIVE COURT DECISION TO INVALIDATE PATENT.BELIEVES EARLIEST LIKELY U.S. GENERIC ENTRY WOULD BE OCTOBER 2018, WHICH IS ALREADY REFLECTED IN THE CONSENSUS OF ANALYSTS.  Full Article

BTG says CFO Rolf Soderstrom to step down as executive director
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BTG PLC ::THAT AFTER 10 YEARS AS CHIEF FINANCIAL OFFICER (CFO) AT BTG, ROLF SODERSTROM IS TO STEP DOWN AS AN EXECUTIVE DIRECTOR OF COMPANY​.‍INTENDS TO APPOINT DUNCAN KENNEDY TO SUCCEED ROLF AS CFO ON 1 JANUARY 2018​.‍ROLF WILL REMAIN WITH COMPANY UNTIL COMPLETION OF A SMOOTH HANDOVER TO DUNCAN, WHICH IS EXPECTED TO BE CONCLUDED BY 31 MARCH 2018​.  Full Article

BTG H1 ‍adjusted operating profit of 99.1 mln stg vs 78.8 mln stg
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Btg Plc :H1 REVENUE 341.3 MILLION STG.H1 ‍ADJUSTED OPERATING PROFIT OF 99.1 MILLION STG VERSUS 78.8 MILLION STG YEAR AGO​.BTG PLC - ‍FURTHER GROWTH IS EXPECTED IN H2 IN INTERVENTIONAL MEDICINE PRODUCT SALES ​.BTG PLC - ‍PHARMACEUTICALS REVENUES IN H2 WILL REFLECT H1-WEIGHTED SEASONALITY OF CROFAB AND FEWER ANTICIPATED EXPIRY ORDERS FOR DIGIFAB COMPARED WITH H2 2016/17​.‍GROUP'S OVERALL OUTLOOK FOR FULL YEAR TO 31 MARCH 2018 REMAINS UNCHANGED​.  Full Article

BTG's Biocompatibles to settle LC Bead probe for $36 mln
Thursday, 6 Oct 2016 

BTG Plc : Settlement of U.S. investigation into LC Bead . Unit Biocompatibles subsidiary reached a settlement with U.S. government in relation to department of justice's investigation of marketing of LC Bead . Says Biocompatibles has agreed to settle all allegations and consequently to pay a total penalty of $36 mln .Investigation focused on period pre-dating BTG's acquisition of Biocompatibles in January 2011.  Full Article

BTG says received approval from Health Canada for DC Bead Lumi
Thursday, 25 Aug 2016 

BTG PLC : Says received approval from Health Canada for DC Bead Lumi . Says anticipates securing regulatory clearances for additional radiopaque bead products in other markets worldwide .Says look forward to providing DC Bead Lumi to Canadian physicians during second half of 2016.  Full Article

Photo

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .